<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03872921</url>
  </required_header>
  <id_info>
    <org_study_id>NUC-5/PSC</org_study_id>
    <nct_id>NCT03872921</nct_id>
  </id_info>
  <brief_title>norUrsodeoxycholic Acid vs Placebo in PSC</brief_title>
  <official_title>Double-blind, Randomized, Placebo-controlled, Phase III Study Comparing norUrsodeoxycholic Acid Capsules With Placebo in the Treatment of Primary Sclerosing Cholangitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Falk Pharma GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. Falk Pharma GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Double-blind, randomized, multi-center, placebo-controlled, comparative, phase III trial. The
      study will be conducted with two treatment groups in the form of a parallel group comparison
      and will serve to compare oral treatment with either 1500 mg/d norursodeoxycholic acid
      capsules or placebo capsules for the treatment of Primary Sclerosing Cholangitis.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 8, 2018</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">April 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>superiority of norursodeoxycholic acid (norUDCA) compared to placebo in the treatment of Primary Sclerosing Cholangitis (PSC)</measure>
    <time_frame>2 years</time_frame>
    <description>prevention of disease progression assessed by partial normalization of serum Alkaline Phosphatase (s-ALP) levels in patients with PSC</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Show superiority of norursodeoxycholic acid (norUDCA) compared to placebo in the treatment of Primary Sclerosing Cholangitis (PSC)</measure>
    <time_frame>2 years</time_frame>
    <description>prevention of disease progression assessed by liver histology</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Primary Sclerosing Cholangitis</condition>
  <arm_group>
    <arm_group_label>norUrsodeoxycholic acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>norUrsodeoxycholic acid 250mg capsules, 6 capsules/day for 2 years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo to norUrsodeoxycholic acid</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>norUrsodeoxycholic acid 250mg Placebo-capsules, 6 capsules/day for 2 years</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>norUrsodeoxycholic Acid</intervention_name>
    <description>oral treatment</description>
    <arm_group_label>Placebo to norUrsodeoxycholic acid</arm_group_label>
    <arm_group_label>norUrsodeoxycholic acid</arm_group_label>
    <other_name>NUC</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent

          -  verified PSC

          -  Liver Biopsy available for Review

          -  If pre-treated with UDCA Patient must be on stable dose not exceeding 20mg/kg/bw

          -  Patients with or without concomittant IBD

        Exclusion Criteria:

          -  History or presence of other concomitant liver diseases

          -  Presence of Cholangiocarcinoma

          -  Secondary causes of Sclerosing Cholangitis

          -  Small Duct Cholangitis in the absence of large duct disease

          -  Any known relevant infectious disease

          -  Abnormal renal function

          -  Any active malignant disease

          -  Known intolerance/hypersensitivity to study drug
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Trauner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Vienna, Department of Internal Medicine III</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Markus Pr√∂ls, PhD</last_name>
    <phone>++49-761-1514</phone>
    <phone_ext>0</phone_ext>
    <email>zentrale@drfalkpharma.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Michael Stiess, PhD</last_name>
    <phone>++49-761-1514</phone>
    <phone_ext>0</phone_ext>
    <email>zentrale@drfalkpharma.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medical University of Vienna, Department of Internal Medicine III</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Trauner, MD</last_name>
      <phone>0043 (0)1 40400</phone>
      <phone_ext>47440</phone_ext>
      <email>michael.trauner@meduniwien.ac.at</email>
    </contact>
    <contact_backup>
      <last_name>Emina Halilbasic, MD</last_name>
      <phone>0043 (0)1 40400</phone>
      <phone_ext>491210</phone_ext>
      <email>emina.halilbasic@meduniwien.ac.at</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Medical School Hannover</name>
      <address>
        <city>Hannover</city>
        <state>Lower Saxonia</state>
        <zip>30623</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heike Bantel, MD</last_name>
      <phone>+49 511 532</phone>
      <phone_ext>9514</phone_ext>
      <email>bantel.heike@mh-hannover.de</email>
    </contact>
    <contact_backup>
      <last_name>Markus Cornberg, MD</last_name>
      <phone>+49 511 532</phone>
      <phone_ext>6821</phone_ext>
      <email>cornberg.markus@mh-hannover.de</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>March 8, 2019</study_first_submitted>
  <study_first_submitted_qc>March 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 13, 2019</study_first_posted>
  <last_update_submitted>October 29, 2019</last_update_submitted>
  <last_update_submitted_qc>October 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 31, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholangitis</mesh_term>
    <mesh_term>Cholangitis, Sclerosing</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>It is not yet decided which data will be made available. Neither a time Frame can be indicated yet.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

